Aligos Therapeutics, Inc.
ALGS
$7.55
-$0.82-9.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.52% | -49.65% | 5.78% | 7.92% | -19.43% |
| Total Depreciation and Amortization | -14.56% | -27.34% | -26.86% | -31.26% | -29.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -184.25% | 251.39% | -140.22% | -128.50% | 105.65% |
| Change in Net Operating Assets | 70.95% | 47.98% | 41.94% | -57.28% | 27.40% |
| Cash from Operations | 0.57% | -2.21% | -16.24% | -21.90% | 2.44% |
| Capital Expenditure | -28.40% | -584.21% | -5.83% | -1.06% | 81.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -200.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 141.53% | -140.33% | -167.29% | -154.46% | -216.56% |
| Cash from Investing | 141.31% | -140.64% | -167.60% | -154.63% | -217.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 29.67% | 13.54% | 32.31% | 16.67% | -68.52% |
| Issuance of Common Stock | 467.86% | -97.57% | 2,984.95% | 2,937.48% | 7,460.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15.63% | -99.60% | 17,091.81% | 17,021.75% | 47,894.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 190.50% | -281.67% | -118.90% | -332.37% | -102.19% |